The Pharmacy Trap

The pill organizer sits on the kitchen counter, seven columns for seven days, each column holding a morning dose and an evening dose. Heart medication, blood pressure medication, a statin, a blood thinner, something for acid reflux, vitamin D. Six prescriptions, none of them optional, all of them indefinite. Multiply that by twelve months, then by twenty or twenty-five years of retirement, and you begin to see the problem.

Ninety percent of Americans over 65 take at least one prescription medication. Forty-two percent take five or more. The average senior fills eighteen prescriptions per year. These are not luxuries or lifestyle choices. They are the chemical infrastructure that keeps chronic disease from becoming acute crisis, that keeps a manageable Tuesday from becoming an ambulance ride on Wednesday.

And for decades, the system that prices those prescriptions has operated with a logic that has nothing to do with what a retired couple on a fixed income can afford.

The Scale of the Problem

#

Total U.S. prescription drug spending reached $600 billion in 2023, up from $393 billion just seven years earlier. Medicare Part D spending alone nearly doubled in less than a decade, from $121 billion in 2014 to $276 billion in 2023, growing at roughly 10% per year. Seniors account for about 14% of the population but more than a third of all prescription spending.

The out-of-pocket burden is real. One in five seniors spent more than $1,000 out of pocket on prescriptions in the past year. KFF survey data from 2023 found that more than a third of Medicare beneficiaries had delayed or gone without medical, dental, vision, hearing, or prescription drug services because of cost. The people skipping doses, splitting pills, or leaving prescriptions unfilled are not failing to comply with medical advice. They are doing arithmetic.

The clinical consequences of that arithmetic are severe. Among seniors, 10 to 30 percent of hospital admissions are related to drug problems, including adverse reactions from medications they are taking and complications from medications they stopped taking because they could not afford them. Adverse drug events send 700,000 Americans to emergency departments and 100,000 into hospitals every year. The pharmacy counter is where medical guidance meets financial reality, and financial reality often wins.

Why American Drugs Cost More

#

The United States has, until very recently, been the only wealthy nation that did not directly negotiate the prices its public insurance programs pay for prescription drugs. Medicare, the largest single purchaser of pharmaceuticals in the country, was explicitly prohibited by law from negotiating drug prices from the time Part D was created in 2003 until the Inflation Reduction Act changed the rules in 2022.

The absence of negotiation meant that drug manufacturers set their own prices, adjusted them upward with little constraint, and passed the costs through a distribution chain that added its own layers of opacity. The intermediaries in that chain, pharmacy benefit managers (PBMs), were supposed to use their purchasing power to negotiate lower prices on behalf of insurers and patients. What they actually did is a story the Federal Trade Commission has been telling in uncomfortable detail.

In January 2025, the FTC released a report on the three largest PBMs (CVS Caremark, Express Scripts, and OptumRx), which together control roughly 80% of the prescription drug market. The findings were blunt. Between 2017 and 2022, these three companies marked up specialty generic drugs by hundreds to thousands of percent above their acquisition costs. The generic version of the cancer drug Gleevec carried a markup of 5,232%. The generic version of the blood pressure drug Adcirca went from an acquisition cost of $27 to a reimbursed price of $2,106, a 7,700% markup. Total revenue above acquisition costs across these three PBMs reached $7.3 billion over that period, growing at a compound annual rate of 42%.

PBMs do not manufacture drugs. They do not dispense them. They sit between manufacturers, insurers, and pharmacies, managing formularies, negotiating rebates, and extracting value at every junction. Their compensation was historically tied to the price of the drugs flowing through their systems, which meant they had a financial incentive to keep prices high even as they claimed to be reducing costs. The gap between what a PBM pays for a drug and what it charges the plan or patient is where the money lives.

International comparison makes the distortion visible. Americans pay roughly two to three times more for the same brand-name drugs than patients in other wealthy nations. A month of Humira that costs $1,400 in the United States costs a fraction of that in Germany, the UK, or Australia. Those countries negotiate prices nationally. The United States, until 2022, did not.

The Inflation Reduction Act: What Actually Changed

#

The Inflation Reduction Act of 2022 represents the most significant change to prescription drug pricing in Medicare’s history. Three provisions matter most.

First, Medicare drug price negotiation. For the first time, Medicare can negotiate prices directly with manufacturers for a select number of high-expenditure drugs. The first round targeted ten drugs, with negotiated prices taking effect January 1, 2026. Those ten drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the NovoLog/Fiasp insulin family) collectively account for billions in annual Medicare spending and are among the most commonly prescribed medications for seniors managing cardiovascular disease, diabetes, blood clotting disorders, and autoimmune conditions.

The price reductions range from 38% to 79% off 2023 list prices. Januvia, a diabetes medication, dropped from $527 to $113 per month. Eliquis, the blood thinner that millions of seniors take daily, fell from $521 to $231. An AARP analysis found that across 56 stand-alone Part D plans, the average cost reduction for these ten drugs was 51%, with seven of the ten falling below $100 per month. CMS projects $6 billion in savings to Medicare and $1.5 billion in reduced out-of-pocket costs for beneficiaries in 2026 alone.

A second round of negotiations, covering fifteen drugs for 2027, has been completed. That list includes Ozempic, the GLP-1 medication for diabetes that has become one of the most expensive drugs in Medicare spending. A third round, targeting twenty drugs for 2028, will for the first time include drugs covered under Part B (physician-administered medications), not just Part D. The Congressional Budget Office estimates total savings of $98.5 billion over the program’s first decade.

Second, the Part D out-of-pocket cap. Before the IRA, Medicare Part D had no annual limit on what beneficiaries could spend out of pocket. The program’s original design included a “donut hole,” a coverage gap where patients paid a large share of their drug costs after reaching an initial spending threshold but before hitting catastrophic coverage. The IRA eliminated the donut hole and, beginning in 2025, imposed a hard cap on annual out-of-pocket spending: $2,000 in 2025, rising to $2,100 in 2026 (adjusted annually for inflation). CMS reports that 3.2 million beneficiaries hit the cap in its first year, saving an average of $1,500 each, with some saving more than $3,000. A new “smoothing” option allows beneficiaries to spread their out-of-pocket costs in equal monthly payments rather than absorbing them all in the first months of the year, when deductibles and high-cost prescriptions often cluster.

Third, the $35 monthly insulin cap. All Part D plans must now cap insulin costs at $35 per month, regardless of the type or quantity. Free vaccines (shingles, RSV, and all ACIP-recommended immunizations) are also now covered with no cost-sharing.

These are real improvements that affect real people at real kitchen tables. They are also the beginning of a process, not the end of one. Ten drugs were negotiated in the first round. Medicare Part D covers thousands. The out-of-pocket cap helps the people with the highest costs but does not reduce premiums or the underlying price of medications. And the insulin cap, while life-changing for diabetics who were rationing doses, does not address the broader pricing dynamics that made rationing necessary in the first place.

The PBM Reckoning

#

While Congress was building the IRA framework, the FTC was building its case against the pharmacy benefit manager industry. The January 2025 report was the public-facing evidence. The policy response came in February 2026, when Congress passed PBM reforms as part of the Consolidated Appropriations Act.

The key provisions delink PBM compensation from drug prices in Medicare Part D, requiring flat bona fide service fees instead of percentage-based rebates that rewarded higher list prices. The law requires 100% rebate pass-through to employer plans, meaning that rebates negotiated by PBMs must flow to the plans and patients rather than being retained as profit. Enhanced transparency and reporting requirements give regulators and plans more visibility into PBM pricing practices. The CBO estimated the reforms would reduce the federal deficit by $2.12 billion over ten years, which gives a sense of how much money was being extracted from the system.

Separately, the FTC secured a settlement with Express Scripts in February 2026 over its insulin pricing practices. States have been acting too. Arkansas banned PBMs from owning pharmacies outright (a bill now under legal challenge). Massachusetts passed comprehensive PBM licensing requirements. Colorado and California enacted laws delinking PBM compensation from drug prices.

The PBM reforms matter because they address the layer of the pricing system that patients never see. A senior picking up a prescription at the pharmacy window encounters a price that has passed through manufacturer list pricing, PBM rebate negotiations, formulary placement decisions, pharmacy reimbursement rates, and plan design choices before it becomes the number on the receipt. Each intermediary takes a cut. The PBM reforms do not eliminate intermediaries, but they change the financial incentives that allowed those intermediaries to profit from complexity at the patient’s expense.

What’s Coming Next: International Reference Pricing

#

In December 2025, CMS proposed two mandatory models that would, for the first time, tie American drug prices to international benchmarks. The GLOBE model (for Part B drugs administered in physician offices) and the GUARD model (for Part D drugs dispensed at pharmacies) would require manufacturers to pay incremental rebates when U.S. prices exceed what 19 comparable OECD nations pay for the same medications.

The benchmarking countries include Australia, Canada, France, Germany, Japan, the UK, and twelve others. GLOBE would cover single-source drugs and biologics in seven therapeutic categories with annual Medicare spending exceeding $100 million, with 62 illustrative drugs identified. GUARD would cover 17 therapeutic classes with annual spending above $69 million. Both models would apply to 25% of Medicare beneficiaries in randomized geographic areas over roughly seven-year periods.

The comment period closes February 23, 2026, and the models are part of the Trump administration’s broader most-favored-nation pricing strategy, following executive orders issued in April and May 2025. Whether GLOBE and GUARD survive the comment period, legal challenges, and pharmaceutical industry opposition is uncertain. If they do, they represent a structural shift: the United States would no longer price drugs in isolation from the rest of the world.

The pharmaceutical industry’s response has been fierce. The argument that price controls will reduce innovation investment is familiar and not entirely wrong; the relationship between drug pricing and research investment is real, though the industry’s claims about the magnitude of the effect have been consistently overstated. The counterargument is that American patients have been subsidizing global pharmaceutical research through inflated prices for decades, and that the rest of the wealthy world manages to both negotiate drug prices and maintain functioning pharmaceutical industries.

The GLP-1 Wildcard

#

No discussion of prescription drug costs in 2026 is complete without addressing the medications that have reshaped the landscape most dramatically: the GLP-1 receptor agonists, marketed as Ozempic, Wegovy, Mounjaro, and Zepbound.

These drugs, originally developed for diabetes, have proven remarkably effective for weight loss and show emerging evidence for cardiovascular and kidney benefits. They have also become among the most expensive drugs in Medicare spending. At list prices of $1,000 to $1,350 per month, widespread Medicare coverage would cost tens of billions annually.

In November 2025, the administration announced pricing agreements with Eli Lilly and Novo Nordisk. Medicare and Medicaid prices for Ozempic, Wegovy, Zepbound, and Mounjaro were set at $245 per month. Medicare beneficiaries with obesity and a related comorbidity will pay a $50 monthly copay. This is the first time Medicare will cover weight-loss medications (federal law still prohibits coverage for weight loss alone; a qualifying comorbidity like diabetes, cardiovascular disease, or sleep apnea is required).

A separate initiative, the TrumpRx direct-to-consumer platform launched in February 2026, offers cash-pay discounts on these and other drugs: Wegovy injections at $199 per month, the oral Wegovy pill (FDA-approved December 2025) at $149, Ozempic at $350, Zepbound at $299. The platform does not replace insurance coverage; it connects patients to manufacturer discount programs and is most useful for those without or with limited coverage.

The BALANCE model, a voluntary program for Part D plans, begins in April 2026 and will expand through CMMI in January 2027. These are meaningful steps. They are also negotiated arrangements with two companies, not systemic reforms to how specialty drugs enter Medicare coverage. The next class of expensive medications, whatever it is, will arrive in the same system.

What You Can Do at Your Kitchen Table

#

The policy landscape is shifting faster than at any point in Medicare’s history. Some of those shifts will reach your pharmacy counter in 2026 and 2027. Others will take years to materialize, if they survive at all. In the meantime, the pill organizer still needs filling and the bills still need paying.

Start with your Part D plan. Review it every year during Open Enrollment (October 15 through December 7). Check whether your medications are on the plan’s formulary, what tier they sit on, and whether a different plan covers them at lower cost. The Medicare Plan Finder tool at medicare.gov lets you enter your specific medications and compare plans by total annual cost. If any of your drugs are among the ten with newly negotiated prices, your costs should drop in 2026, but the amount depends on your specific plan structure.

Ask your doctor about generic alternatives. Forty-two percent of seniors take five or more medications, and for many of those prescriptions, a generic or therapeutic equivalent exists at a fraction of the brand-name cost. A pharmacist-led medication review (ask your doctor or pharmacist to schedule one) can identify drugs that can be switched, doses that can be consolidated, and prescriptions that may no longer be necessary. One in five seniors is currently taking at least one medication classified as potentially inappropriate for their age group. Deprescribing, the supervised reduction or elimination of unnecessary medications, is a growing area of clinical practice that can reduce costs and improve outcomes simultaneously.

If your drug costs are high, check whether you qualify for Medicare Extra Help (also called the Low-Income Subsidy), which covers Part D premiums, deductibles, and copays for beneficiaries below certain income and asset thresholds. Many people who qualify never apply. State Pharmaceutical Assistance Programs (SPAPs) and manufacturer patient assistance programs can provide additional relief.

Use the new smoothing option. If your out-of-pocket costs tend to cluster early in the year when deductibles reset and high-cost prescriptions renew, the monthly payment smoothing provision allows you to spread those costs evenly across the year rather than absorbing them all in January and February.

And pay attention. The next three years will bring more negotiated drug prices, potential international reference pricing, continued PBM reform, and expanded GLP-1 coverage. These changes will not fix every problem described in this article. But they represent the first sustained effort in decades to bring the cost of staying alive on six medications per day into some relationship with what a retired person can actually pay.

The pill organizer on the counter is not going away. The question is whether the system that prices what goes into it will finally begin to make sense.